Top

Reactions Weekly

Published in:

01-12-2013 | Case report

Hydroxycarbamide

Pyoderma gangrenosum treated with ruxolitinib: case report

Published in: Reactions Weekly | Issue 1/2013

Excerpt

Author Information

An event is serious (FDA MedWatch definition) when the patient outcome is:

* death
* life-threatening
* hospitalisation
* disability
* congenital anomaly
* requires intervention to prevent permanent impairment or damage

…

Shanmugam VK, et al. Chronic Leg Ulceration Associated with Polycythemia Vera Responding to Ruxolitinib (Jakafi). Journal of Foot and Ankle Surgery: Official Publication of the American College of Foot and Ankle Surgeons 52: 781-785, No. 6, Nov-Dec 2013. Available from: URL: http://dx.doi.org/10.1053/j.jfas.2013.07.003 - USACrossRef

Title: Hydroxycarbamide
Pyoderma gangrenosum treated with ruxolitinib: case report
Publication date: 01-12-2013
Publisher: Springer International Publishing
Published in: Reactions Weekly / Issue 1/2013
Print ISSN: 0114-9954
Electronic ISSN: 1179-2051
DOI: https://doi.org/10.1007/s40278-013-7754-7

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Hydroxycarbamide

Pyoderma gangrenosum treated with ruxolitinib: case report

Excerpt

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 1/2013

Fluorouracil/folinic acid/oxaliplatin

Prasugrel

Stronger drug quality and safety laws in the US

Sulprostone

Ceftriaxone

Alendronic acid overdose